At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

Acute lymphoblastic leukemia (ALL) represents around 70% of pediatric leukemia. In high-income countries, the 5-year survival is above 90%, but survival in low- and middle-income countries is inferior ...

The National Comprehensive Cancer Network guidelines for pediatric and adult acute lymphoblastic leukemia (ALL) provide recommendations on standard treatment approaches based on the current evidence.

Highlights in acute lymphoblastic leukemia (ALL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, include studies on pediatric and adult disease, as discussed ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring ...

Acute lymphoblastic leukemia (ALL) may be confused with different types of hematological conditions. Confusion of ALL diagnosis with acute myeloid leukemia (AML), hairy cell leukemia and malignant ...

Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial Studying 767 children ...

Credit: Getty Images ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.